Your session is about to expire
What is Restasis Multidose
CyclosporineThe Generic name of this drug
Treatment SummaryCyclosporine is a medication used to prevent organ rejection in transplant patients and treat certain autoimmune and inflammatory conditions. It is derived from a fungus called _Beauveria nivea_ and was first introduced in 1983 by the pharmaceutical company Sandoz (now Novartis).
Sandimmuneis the brand name
Restasis Multidose Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sandimmune
Cyclosporine
1983
68
Approved as Treatment by the FDA
Cyclosporine, also known as Sandimmune, is approved by the FDA for 20 uses which include Patients who do not adequately respond to methotrexate alone and Liver .Patients who do not adequately respond to methotrexate alone
Used to treat Patients who do not adequately respond to methotrexate alone in combination with Methotrexate
Liver
Not responsive to other therapy
Helps manage Not responsive to other therapy
Prophylaxis against graft versus host disease
Bone Marrow Transplantation
Heymann Nephritis
Helps manage Glomerulonephritis, Membranous
Transplantation
Chronic Graft Versus Host Disease
Therapeutic immunosuppression
Prophylaxis against stem cell transplant rejection
Prophylaxis against heart transplant rejection
severe, recalcitrant Plaque psoriasis
Helps manage severe, recalcitrant Plaque psoriasis
Rheumatoid Arthritis
Helps manage severe, active Rheumatoid arthritis
Nephrotic Syndrome
Helps manage Nephrotic Syndrome
Bone Marrow
Glomerulosclerosis, Focal Segmental
Helps manage Focal Segmental Glomerulosclerosis (FSGS)
Glomerulosclerosis
Helps manage Glomerulosclerosis
Kidney Transplantation
Nephrotic Syndrome
Helps manage Steroid Resistant Nephrotic Syndrome
Nephrotic Syndrome
Helps manage Steroid Dependent Nephrotic Syndrome
Effectiveness
How Restasis Multidose Affects PatientsCyclosporine helps to stop or reduce the effects of serious immune system reactions, such as after an organ transplant or bone marrow transplant. Common side effects include excessive hair growth, swollen gums, and high cholesterol levels. There is some concern that taking this drug may damage the kidneys.
How Restasis Multidose works in the bodyCyclosporine works by preventing T cells from becoming active and causing inflammation. It does this by preventing a certain receptor from binding to a protein called calcineurin, which helps activate T cells. This stops the production of cytokines, which are molecules that cause inflammation. It also lowers the levels of other molecules involved in T cell function and development.
When to interrupt dosage
The prescribed quantity of Restasis Multidose is dependent on the diagnosed circumstance, such as Interstitial Cystitis, Focal Segmental Glomerulosclerosis (FSGS) and Excessive tearing. The dose is contingent upon the modality of administration (e.g. Liquid - Intravenous or Ophthalmic; Topical) presented in the table below.Condition
Dosage
Administration
Heymann Nephritis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Cystitis, Interstitial
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Bone Marrow
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Disease
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Bone Marrow Transplantation
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Nephrotic Syndrome
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Nephrotic Syndrome
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Prophylaxis against stem cell transplant rejection
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Dry Eye Syndromes
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Not responsive to other therapy
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Transplantation
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Ulcerative Colitis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Chronic Graft Versus Host Disease
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Organ Transplantation
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Rosacea
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Patients who do not adequately respond to methotrexate alone
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Therapeutic immunosuppression
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Conjunctivitis, Allergic
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Juvenile arthritis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Nephrotic Syndrome
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Warnings
Restasis Multidose ContraindicationsCondition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Psoriasis
Do Not Combine
Abnormal Renal Function
Do Not Combine
Hypertensive disease
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Cyclosporine may interact with Pulse Frequency
Common Restasis Multidose Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Cyclosporine.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Cyclosporine.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Cyclosporine.
Aliskiren
Major
The serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Cyclosporine.
Restasis Multidose Toxicity & Overdose RiskThe toxic dose of cyclosporine in rats is 1480mg/kg, and the lowest toxic dose in humans is 12mg/kg. If someone takes too much cyclosporine, it is recommended to induce vomiting and perform a stomach lavage within 2 hours. There is not much information available about the effects of cyclosporine overdose, but it can lead to liver and kidney damage. In one case, a 26 year old woman experienced nausea, flushing, tremor, vertigo, and vomiting which resolved within 1 day. Anorexia and feeling of increased body girth were also reported and resolved within 2
Restasis Multidose Novel Uses: Which Conditions Have a Clinical Trial Featuring Restasis Multidose?
81 active trials are studying the potential of Restasis Multidose to provide therapeutic benefits for patients with Chronic Graft Versus Host Disease, Kidney Diseases and Ulcerative Colitis.Condition
Clinical Trials
Trial Phases
Therapeutic immunosuppression
0 Actively Recruiting
Rheumatoid Arthritis
0 Actively Recruiting
Bone Marrow
1 Actively Recruiting
Early Phase 1
severe, recalcitrant Plaque psoriasis
0 Actively Recruiting
Nephrotic Syndrome
11 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3
Disease
0 Actively Recruiting
Prophylaxis against graft versus host disease
0 Actively Recruiting
Liver
0 Actively Recruiting
Heymann Nephritis
3 Actively Recruiting
Phase 2, Phase 1
Glomerulosclerosis
0 Actively Recruiting
Prophylaxis against heart transplant rejection
0 Actively Recruiting
Organ Transplantation
0 Actively Recruiting
Excessive tearing
0 Actively Recruiting
Transplantation
0 Actively Recruiting
Lupus Nephritis
23 Actively Recruiting
Phase 3, Phase 2, Phase 1, Not Applicable
Not responsive to other therapy
0 Actively Recruiting
Kidney Transplantation
0 Actively Recruiting
Glomerulosclerosis, Focal Segmental
12 Actively Recruiting
Not Applicable, Phase 3, Early Phase 1, Phase 2, Phase 1
Uveitis
5 Actively Recruiting
Phase 4, Not Applicable, Phase 2, Phase 1, Phase 3
Nephrotic Syndrome
0 Actively Recruiting
Restasis Multidose Reviews: What are patients saying about Restasis Multidose?
3.3Patient Review
6/30/2018 The Restasis multidose dispenser bottle is not user-friendly. Too difficult to squeeze, and drops are wasted on the bottle nipple. I went back to single dose - which was easier to use and lasted much longer.
3.3Patient Review
6/30/2018 The Restasis multidose dispenser bottle was not easy to use. I ended up wasting a lot of medication because it was difficult to control the amount of drops that came out.
3Patient Review
7/2/2022 I wasn't thrilled with the design of the bottle. It seems like it would be easy to waste product. I'm going to try a generic brand next time.
3Patient Review
7/2/2022 The multi-use bottle is very poorly designed. A cynical person might say that it was designed to waste product. I am going to try the generic cyclosporine.
2.7Patient Review
2/26/2022 I've been using Restasis for years with the single-dose vials and never had a problem. The new multi-dose bottle is terrible. You have to squeeze it so hard to get anything to come out, and then more than one drop comes out. I can already tell this bottle won't last thirty days. They need to fix this!
2.7Patient Review
2/26/2022 I've been using Restasis for years with the single-dose vials, and I never had a problem. The new multi-dose bottle is terrible. You have to squeeze it so hard to get anything to come out, and then more than one drop comes out. I can already tell this bottle won't last thirty days. They need to fix this!
2.7Patient Review
4/2/2022 The drops are hard to dispense and the bottle doesn’t last but 20 days. This is very expensive for such a short amount of time, and I won't be buying it again.
2.7Patient Review
4/2/2022 The drops are hard to dispense and the bottle doesn’t last but 20 days, which is very expensive. Will not buy again.
2Patient Review
8/9/2018 The single-use doses of this medication were great, but I ran into issues when trying to use the bottle. The amount in each bottle never lasted long enough, and I often went weeks without any relief. Additionally, the price per month skyrockets if you need to use the individual vials rather than the bottles. Suffering from dry eyes is no fun, especially when you don't have access to your needed medication!
2Patient Review
8/9/2018 The single-use doses were great, but when I moved to the bottle usage, it was awful. I never had enough drops, and would go weeks without any relief. The program is terrible - it only offers $5 if you use the bottles, and then goes up to $30 per month for the individual vials that work out in giving a 30 day supply as needed. I'm very unhappy and will be contacting my doctor to see if there is a different medication I can use. Suffering is not fun, especially when all you need is some eye drop relief!
1.7Patient Review
10/2/2022 The multi-dose container is very difficult to use, even for nurses with years of experience. I'm only supposed to use one drop in each eye, but it's impossible to control the amount that comes out. As a result, I go through this medication much faster than I should.
1.7Patient Review
6/19/2021 The multi-dose version of this medication was very difficult to use and only lasted me 20 days, even though it is supposed to be a 30 day supply. In addition, it did not help at all with my dry eye problem. I'm considering trying the single vial next, even though it's more expensive.
1.7Patient Review
10/2/2022 I completely agree with the other negative reviews about how hard it is to get the right amount of medication out of the container. Even for a nurse with steady hands, it's impossible to use as directed. This product is clearly designed to make more money off of customers by not lasting very long.
1.7Patient Review
6/19/2021 I found the multi-dose version to be very difficult to use, and it only lasted me 20 days instead of the 30 it was supposed to. Plus, it did nothing to help my dry eyes. I'm considering switching to the single-vial option, even though it's more expensive.
1.7Patient Review
8/30/2022 The container design is really poor. You have to squeeze too hard for the product to come out, and then way too much comes out! Additionally, it's very difficult to get the product in my eyes. Awful!!
1.7Patient Review
8/30/2022 The multi-use container is a joke. You have to squeeze really hard for anything to come out and then way too much comes out AND it’s impossible to get it right in my eyes. Awful!!
Patient Q&A Section about restasis multidose
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.How much does Restasis MultiDose cost?
"The price of RESTASIS and RESTASIS MultiDose is $645.63 per month, plus any additional pharmacy charges depending on where you purchase your medicine."
Answered by AI
How many drops are in a Restasis MultiDose bottle?
"A bottle of Restasis MultiDose contains approximately 120 doses or drops. The recommended dosage is one drop into each eye twice daily. This means that one bottle should last a little over 30 days."
Answered by AI
What is the difference between Restasis and Restasis MultiDose?
"The preservative-free formulation of RESTASIS that doctors have prescribed 6.4 million times since 2003 is available in a patented bottle design. Compared to the single-use vials of RESTASIS, the MultiDose version is more compact, uses less plastic in packaging, and is the same price."
Answered by AI